7-Methylsulfanyl-1,2,3,4-tetrahydro-isoquinoline | 170288-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 7-Methylsulfanyl-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: 7-methylsulfanyl-1,2,3,4-tetrahydroisoquinoline
• CAS: 170288-30-9
• 化学式: C₁₀H₁₃NS
• 分子量: 179.286
• InChiKey: XXVAZHMAHYNQBC-UHFFFAOYSA-N

物化性质

• 沸点：
  300.8±42.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-Methylsulfanyl-1,2,3,4-tetrahydro-isoquinoline 在 三氟过氧乙酸 、 三氟乙酸 作用下， 反应 24.0h， 以84.9%的产率得到1,2,3,4-四氢-7-(甲磺酰基)异喹啉
  参考文献：
  名称：

  Synthesis, Biochemical Evaluation, and Classical and Three-Dimensional Quantitative Structure−Activity Relationship Studies of 7-Substituted-1,2,3,4-tetrahydroisoquinolines and Their Relative Affinities toward Phenylethanolamine N-Methyltransferase and the α₂-Adrenoceptor^,1

  摘要：

  7-Substituted-1,2,3,4-tetrahydroisoquinolines (7-substituted-THIQs) are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), the enzyme involved in the biosynthesis of epinephrine. Unfortunately, most of these compounds also exhibit strong affinity for the aa-adrenoceptor. To design a selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitor of PNMT, the steric and electrostatic factors responsible for PNMT inhibitory activity and alpha(2)-adrenoceptor affinity were investigated by evaluating a number of 7-substituted-THIQs. A classical quantitative structure-activity relationship (QSAR) study resulted in a three-parameter equation for PNMT (PNMT pK(i) = 0.599 pi - 0.0725MR + 1.55 sigma(m) + 5.80; n = 27, r = 0.885, s = 0.573) and a three-parameter equation for the alpha(2)-adrenoceptor (alpha(2) pK(i) = 0.599 pi - 0.0542MR - 0.951 sigma(m) + 6.45; n = 27, r = 0.917, s = 0.397). These equations indicated that steric effects and lipophilicity play a similar role at either active site but that electronic effects play opposite roles at either active site. Two binding orientations for the THIQs were postulated such that lipophilic and hydrophilic 7-substituents would not occupy the same region of space at either binding site. Using these two binding orientations, based on the lipophilicity of the 7-substituent, comparative molecular field analysis (CoMFA) models were developed that showed that the steric and electrostatic interactions at both sites were similar to those previously elaborated in the QSAR analyses. Both the QSAR and the CoMFA analyses showed that the steric interactions are similar at the PNMT active site and at the alpha(2)-adrenoceptor and that the electrostatic interactions were different at the two sites. This difference in electrostatic interactions might be responsible for the selectivity of THIQs bearing a nonlipophilic electron-withdrawing group at the 7-position, These QSAR and CoMFA results will be useful in the design of potent and selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitors of PNMT.

  DOI：

  10.1021/jm980429p
• 作为产物：
  描述：

  7-氨基-1,2,3,4-四氢异喹啉 在 盐酸 、 4-二甲氨基吡啶 、 正丁基锂 、 氢溴酸 、 三乙胺 、 copper(I) bromide 、 sodium nitrite 作用下， 以 二氯甲烷 为溶剂， 反应 19.5h， 生成 7-Methylsulfanyl-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  Synthesis, Biochemical Evaluation, and Classical and Three-Dimensional Quantitative Structure−Activity Relationship Studies of 7-Substituted-1,2,3,4-tetrahydroisoquinolines and Their Relative Affinities toward Phenylethanolamine N-Methyltransferase and the α₂-Adrenoceptor^,1

  摘要：

  7-Substituted-1,2,3,4-tetrahydroisoquinolines (7-substituted-THIQs) are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), the enzyme involved in the biosynthesis of epinephrine. Unfortunately, most of these compounds also exhibit strong affinity for the aa-adrenoceptor. To design a selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitor of PNMT, the steric and electrostatic factors responsible for PNMT inhibitory activity and alpha(2)-adrenoceptor affinity were investigated by evaluating a number of 7-substituted-THIQs. A classical quantitative structure-activity relationship (QSAR) study resulted in a three-parameter equation for PNMT (PNMT pK(i) = 0.599 pi - 0.0725MR + 1.55 sigma(m) + 5.80; n = 27, r = 0.885, s = 0.573) and a three-parameter equation for the alpha(2)-adrenoceptor (alpha(2) pK(i) = 0.599 pi - 0.0542MR - 0.951 sigma(m) + 6.45; n = 27, r = 0.917, s = 0.397). These equations indicated that steric effects and lipophilicity play a similar role at either active site but that electronic effects play opposite roles at either active site. Two binding orientations for the THIQs were postulated such that lipophilic and hydrophilic 7-substituents would not occupy the same region of space at either binding site. Using these two binding orientations, based on the lipophilicity of the 7-substituent, comparative molecular field analysis (CoMFA) models were developed that showed that the steric and electrostatic interactions at both sites were similar to those previously elaborated in the QSAR analyses. Both the QSAR and the CoMFA analyses showed that the steric interactions are similar at the PNMT active site and at the alpha(2)-adrenoceptor and that the electrostatic interactions were different at the two sites. This difference in electrostatic interactions might be responsible for the selectivity of THIQs bearing a nonlipophilic electron-withdrawing group at the 7-position, These QSAR and CoMFA results will be useful in the design of potent and selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitors of PNMT.

  DOI：

  10.1021/jm980429p

文献信息

• Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
  申请人：CTXT PTY LTD

  公开号：US10005792B2

  公开（公告）日：2018-06-26

  A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(═O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式（1a）、（1b）或（1c）化合物 其中：n 为 1 或 2；RN 为 H 或 Me；R1 可任选为一个或多个卤代或甲基；R2a 和 R2b 独立选自以下组：(i) F；(ii) H；(iii) Me；和 (iv) CH2OH；R2c 和 R2d（如存在）独立选自以下组：(i) F；(ii) H；(iii) Me；和 (iv) CH2OH；R3a 和 R3b 独立选自 H 和 Me；R4a 选自 OH、-NHH 或 Me：(R3a和R3b独立选自H和Me；R4a选自OH、-NH2、-C(═O)NH2和-CH2OH；R4b不是H就是Me；R5不是H就是Me；A是(i)任选取代的苯基；(ii)任选取代的萘基；或(iii)任选取代的C5-12杂芳基。
• Benzazepine compounds, conjugates, and uses thereof
  申请人：Silverback Therapeutics, Inc.

  公开号：US10428045B2

  公开（公告）日：2019-10-01

  Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.

  本文公开了用于治疗癌症等疾病的苯并氮杂卓化合物、共轭物和药物组合物。所公开的苯并氮杂卓化合物主要用于治疗癌症和调节 TLR8。此外，本文还描述了与抗体构建体结合的苯并氮杂卓化合物。
• Nectin-4 antibody conjugates and uses thereof
  申请人：Silverback Therapeutics, Inc.

  公开号：US11179473B2

  公开（公告）日：2021-11-23

  The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

  本公开提供了抗Nectin-4抗体或其抗原结合片段与髓细胞激动剂的共轭物、包含这些共轭物的组合物以及用这些共轭物治疗癌症的方法。本公开还提供了抗Nectin-4抗体或其抗原结合片段，以及使用该抗体或其抗原结合片段治疗癌症的方法。
• Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11332473B2

  公开（公告）日：2022-05-17

  This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.

  本发明提供了式 (I) 的取代吡唑并[3,4-d]嘧啶化合物： 作为 Wee1 抑制剂。取代的吡唑并[3,4-d]嘧啶化合物可用作治疗疾病的药物。取代的吡唑并[3,4-d]嘧啶化合物还可用于肿瘤学。
• [EN] TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] MODULATEURS DE L'ACTIVITE DES RECEPTEURS DES CHIMIOKINES A BASE DE TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE
  申请人：——

  公开号：WO2003093231A3

  公开（公告）日：2004-08-12